Veeva SystemsVEEV
About: Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Employees: 7,172
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
39% more first-time investments, than exits
New positions opened: 128 | Existing positions closed: 92
33% more funds holding in top 10
Funds holding in top 10: 12 [Q2] → 16 (+4) [Q3]
12% more capital invested
Capital invested by funds: $23.5B [Q2] → $26.4B (+$2.9B) [Q3]
10% more repeat investments, than reductions
Existing positions increased: 352 | Existing positions reduced: 320
4% more funds holding
Funds holding: 898 [Q2] → 934 (+36) [Q3]
9% less call options, than puts
Call options by funds: $248M | Put options by funds: $272M
1.73% less ownership
Funds ownership: 79.41% [Q2] → 77.67% (-1.73%) [Q3]
Research analyst outlook
18 Wall Street Analysts provided 1 year price targets over the past 3 months
18 analyst ratings
Morgan Stanley Craig Hettenbach 60% 1-year accuracy 3 / 5 met price target | 8%downside $195 | Underweight Maintained | 17 Dec 2024 |
JP Morgan Anne Samuel 44% 1-year accuracy 15 / 34 met price target | 2%upside $218 | Neutral Maintained | 16 Dec 2024 |
Citigroup Tyler Radke 63% 1-year accuracy 39 / 62 met price target | 44%upside $307 | Buy Maintained | 9 Dec 2024 |
Mizuho Steven Valiquette 20% 1-year accuracy 1 / 5 met price target | 32%upside $280 | Outperform Maintained | 9 Dec 2024 |
Scotiabank Allan Verkhovski 50% 1-year accuracy 3 / 6 met price target | 13%upside $240 | Sector Perform Maintained | 6 Dec 2024 |
Financial journalist opinion
Based on 23 articles about VEEV published over the past 30 days
